CJC-1295 Meds

// MODULE 07 // REFERENCE INDEX

CJC-1295 Cited Sources

Every claim in the digest ties back to one of these entries. DOIs and PubMed identifiers where available.

Read the researchOpen dosage

Sources cited in the CJC-1295 research digest

Every quantitative claim on this site — every dose, half-life, percent change, study population — ties to one of the entries below. The list is rendered as a numbered reference index in the assembler. CJC-1295 has a small primary-source footprint; the Teichman 2006 JCEM trial is the single dominant human pharmacokinetic study, with the Alba 2006 GHRH-knockout mouse paper as the principal preclinical anchor [1][3]. The remaining entries are analytical-chemistry detection methods, regulatory documents, comparison-compound benchmarks (sermorelin, tesamorelin), and the Van Hout 2016 netnography of community-reported use patterns [7][9][15].

For the latest regulatory state, the FDA's 2024 Pharmacy Compounding Advisory Committee briefing and the September 2024 Category 2 removal announcement are the two primary federal-record entries [13][16]. WADA's 2024 Prohibited List is the source for the Section S2 status [10].

  1. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults. J Clin Endocrinol Metab. 2006;91(3):799-805. ↗
  2. Raun K, Hansen BS, Johansen NL, Thogersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. ↗
  3. Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-E1294. ↗
  4. Bilezikjian LM, Vale WW. Growth hormone-releasing factor-sensitive adenylate cyclase system of purified somatotrophs: effects of guanine nucleotides, somatostatin, calcium, and magnesium. Endocrinology. 1989. ↗
  5. Ionescu M, Frohman LA. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res. 2009. ↗
  6. Coy DH, Murphy WA, Lance VA, Heiman ML. Incorporation of D-Ala2 in growth hormone-releasing hormone-(1-29)-NH2 increases the half-life and decreases metabolic clearance in normal men. J Clin Endocrinol Metab. 1994. ↗
  7. Sermorelin pharmacokinetics — product monograph and review. FDA-approved labeling, Geref (sermorelin acetate). 1997. ↗
  8. Henninge J, Pepaj M, Hullstein I, Hemmersbach P. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug Test Anal. 2010;2(11-12):647-650. ↗
  9. Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, Berger D, Brown S, Richmond G, Fessel J, Turner R, Grinspoon S. Effects of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. N Engl J Med. 2007. ↗
  10. World Anti-Doping Agency. World Anti-Doping Code International Standard — The Prohibited List. 2024. ↗
  11. Sigalos JT, Pastuszak AW, Allison A, Ohlander SJ, Herati A, Lindgren MC, Lipshultz LI. Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels. Am J Mens Health. 2017. ↗
  12. Memdouh S, Ghosh D, Petrou M, Daly L, Cowan D, Brailsford AD. Advances in the detection of growth hormone releasing hormone synthetic analogs. Drug Test Anal. 2021. ↗
  13. U.S. Food and Drug Administration. FDA Briefing Document — Pharmacy Compounding Advisory Committee (PCAC) Meeting — Peptide bulk drug substances review. Regulations.gov docket FDA-2024-N-4777. 2024. ↗
  14. Esposito S, Deventer K, Van Eenoo P. Chromatographic-mass spectrometric analysis of peptidic analytes (2-10 kDa) in doping control urine samples. Drug Test Anal / J Chromatogr B. 2024. ↗
  15. Van Hout MC, Hearne E. Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions. Subst Use Misuse. 2016;51(1):73-84. ↗
  16. U.S. Food and Drug Administration. FDA removes certain peptide bulk drug substances from Category 2 of interim 503A bulks list and sets dates for PCAC review. Federal Register / FDA announcement. 2024. ↗
  17. National Center for Biotechnology Information. CJC-1295 — PubChem CID 91971820. 2024. ↗